High cholesterol levels are a health risk, because of the increased chances of cardiovascular diseases. But research shows that low cholesterol can also be harmful. Researchers from Radboud university medical center and their Australian and American colleagues discovered a new metabolic defect, producing very low cholesterol levels. This causes brain anomalies, developmental delay, epilepsy and typical facial deformities.When physicians at the Wesley Hospital in Brisbane, Australia, studied the urinalysis of one of their patients, they discovered a different profile of the organic acids that they could not quite explain. Could it be possible that the profile was connected to the cause of the disorder? They decided to contact chemist Ron Wevers, who had developed a technique at Radboud university medical center (NMR spectroscopy) with which substances in the urine can be detected in great detail, even when the quantities are very small.
Faltering enzymeWevers: “The combination of the substances we found indicated that there was something wrong with the cholesterol production. Cholesterol enters our system through the food we eat, but the body itself is also capable of producing it. Apparently something went wrong in that process. It turned out that the enzyme that converts farnesol into squalene was not working properly. The urine contained far too much of the first substance and far too little of the second substance. The enzyme squalene synthase is the driving force of this conversion, so that is where we had to look to locate the problem.”
Genetic surpriseWevers was able to locate a second family suffering from the same defect. A total of three patients were found at the time suffering from the same disorder. If the enzyme squalene synthase (SS) is indeed the culprit, then it should be possible to find mutations in the gene FDFT 1, which is the gene that codes for the SS. However, the genetic research caused the researchers to be surprised. Wevers: “We found mutations in one family that disturbed the effect of the enzyme, but we did not find those in the other family. That was a mystery that we were unable to solve for a long time.”
The solving of the mysteryThe mystery was solved at long last by the research group of Lisenka Vissers of the Department of Genetics. Vissers: “A mutation causing a malfunctioning protein can usually be found in the gene itself. But in the second family the mutation was located outside the gene, which was why it had not been found in earlier genetic studies. This mutation prevents the gene for SS, which in essence is perfectly alright, to be read. That explains why the enzyme squalene synthase does not work after all. Mystery solved.”
DiagnosticsThe researchers have used this knowledge to develop a test that will make it easier to find new patients in the currently used urinalyses.
Publication in The American Journal of Human Genetics: Squalene Synthase Deficiency: Clinical, Biochemical, and Molecular Characterization of a Defect in Cholesterol Biosynthesis.
Related news items
Step-up approach vs open necrosectomy for necrotizing pancreatitis18 April 2019
Another publication of the successful Dutch collaborative group on pancreatitis research with substantial contribution from Radboudumc researchers, Harry van Goor and Kees van Laarhoven.read more
Prophylactic antibiotics reduce hospitalisations and cost in head and neck cancer patients18 April 2019
In European journal of cancer Janneke Ham and colleagues showed that prophylactic antibiotics in locally advanced head and neck cancer patients treated with chemoradiotherapy did not reduce the incidence of (aspiration) pneumonias, but did reduce hospitalisations and tended to be cost-effective.read more
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.read more
ESCMID award for groundbreaking studies on NTM disease18 April 2019
Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.read more
EU funded project BIOMAP led by Ellen van den Bogaard12 April 2019
Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.read more